Carla Williams
Psychiatric/Mental Health · New York, NYNPI 1992211577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,070, 3.5 times the $868 reported in 2021. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1000
- Alkermes, Inc.$980
- E.r. Squibb & Sons, L.L.C.$726
- Johnson & Johnson$579
- plus $2K from 11 others
What the payments were for
- Food & beverage$7,57896%
- Education$3564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $1,674 |
| Teva Pharmaceuticals USA, Inc. | 56 | $1,346 |
| Lundbeck LLC | 60 | $1,000 |
| Alkermes, Inc. | 45 | $980 |
| E.r. Squibb & Sons, L.L.C. | 40 | $726 |
| Johnson & Johnson | 26 | $579 |
| Neurocrine Biosciences, Inc. | 18 | $551 |
| Otsuka America Pharmaceutical, Inc. | 21 | $462 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $180 |
| Vanda Pharmaceuticals Inc. | 8 | $149 |
| Sunovion Pharmaceuticals Inc. | 10 | $144 |
| Noven Therapeutics, LLC | 2 | $29 |
| Tonix Medicines, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Validus Pharmaceuticals LLC | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,934 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 61 | $154,706 |
| VraylarCariprazine Hcl | 76 | $106,310 |
| RexultiBrexpiprazole | 45 | $64,030 |
| TrintellixVortioxetine Hydrobromide | 36 | $20,044 |
| Aripiprazole | 177 | $7,185 |
| QuviviqDaridorexant Hcl | 14 | $6,593 |
| Lurasidone Hcl | 29 | $6,370 |
| Asenapine Maleate | 11 | $2,582 |
| Bupropion XlBupropion Hcl | 133 | $1,868 |
| Quetiapine Fumarate | 180 | $1,779 |
| Mirtazapine | 113 | $1,525 |
| Eszopiclone | 13 | $1,432 |
| Atomoxetine Hcl | 11 | $1,195 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $1,115 |
| Chlorpromazine Hcl | 16 | $980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $579 | $154,70661 claims |
| AbbVieVraylar | $1,674 | $106,31076 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $462 | $64,03045 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $27 | $20,04436 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $20 | $6,59314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in New York
- Richard CalladoNew York$47K
- Darcy LeonNew York$37K
- Angela AnukamNew York$11K
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.